helen88的个人主页 - 老虎社区

helen88

暂无个人介绍

IP属地：未知

74关注

6粉丝

4主题

0勋章

2021-01-27

$Sorrento Therapeutics Inc.(SRNE)$必须见$35

2020-04-02

$嘉年华邮轮(CCL)$买入ccl游轮股是一次高风险又是高回报的大机遇

2020-09-30

$Sorrento Therapeutics Inc.(SRNE)$这次上升的更稳

2020-05-08

今天油价的利好能抵挡历史性最差的非农吗？大家有什么看法，我认为基本大利空已不具备，今晚市场会走好。

2020-04-11

下周油股应该看多

2020-04-09

AAON艾伦建材可留意

2021-06-18

$Sorrento Therapeutics Inc.(SRNE)$怎么看

2021-01-28

$Sorrento Therapeutics Inc.(SRNE)$目标越来越近

2020-08-11

$Sorrento Therapeutics Inc.(SRNE)$终于站上18元

2020-06-14

燃石医学开涨43.64%，后面的行情会怎么走呢？

2020-06-13

惊心动魄的一周在最后半小时给了往后行情一根定海神针。

2020-05-24

港板国安法对全球影响不容勿视

2020-05-13

今年就是各种耍嘴皮。

传美国又向中国芯片动手，对中芯、华虹等启动无限追溯

2020-05-12

$诺瓦瓦克斯医药(NVAX)$这股估计得百元才能消停

2020-05-11

台积电会在五月创新高吗？我认为机会有八成，你认为呢？

2020-05-10

FB应该有一波行情启动

Facebook董事会大洗牌，看小扎如何控制社交帝国

2020-05-05

今天油股都在涨，不过得小心哦，开始涨跌不一了

2020-04-30

看来今年大选各方布局都是拼命把各自的饼画得又大又美

2020-08-10

$Sorrento Therapeutics Inc.(SRNE)$我也成绩不错

2020-04-29

赌场是在困景中恢复最快的行业，一半本金在股市，一半就去赌场买一手大小[龇牙] [龇牙] [龇牙]

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3542328439002885,"uuid":"3542328439002885","gmtCreate":1579237855177,"gmtModify":1579237855177,"name":"helen88","pinyin":"helen88","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":74,"tweetSize":70,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.28","exceedPercentage":"93.07%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":168615926,"gmtCreate":1623973821065,"gmtModify":1623973821065,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","text":"$Sorrento Therapeutics Inc.(SRNE)$怎么看","images":[{"img":"https://static.tigerbbs.com/99037d09bdee63c58835fa40503ef6c3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168615926","isVote":1,"tweetType":1,"viewCount":2188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":329638955,"gmtCreate":1615238608577,"gmtModify":1703486064049,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>挣💰去买SRNE","listText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>挣💰去买SRNE","text":"$游戏驿站(GME)$挣💰去买SRNE","images":[{"img":"https://static.tigerbbs.com/d7c4a38fe80797b37bb4e9d2eb18a442","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/329638955","isVote":1,"tweetType":1,"viewCount":1612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":361313692,"gmtCreate":1614204167416,"gmtModify":1614204167416,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>这谁能想到呢","listText":"<a href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>这谁能想到呢","text":"$游戏驿站(GME)$这谁能想到呢","images":[{"img":"https://static.tigerbbs.com/5fcf40c3de359990987a137571c6469f","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/361313692","isVote":1,"tweetType":1,"viewCount":1194,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":383913118,"gmtCreate":1612828753134,"gmtModify":1703765524356,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>现在上车还有机会","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>现在上车还有机会","text":"$Sorrento Therapeutics Inc.(SRNE)$现在上车还有机会","images":[{"img":"https://static.tigerbbs.com/e5fd2ba5ef4302e557ef6f55cca3798d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/383913118","isVote":1,"tweetType":1,"viewCount":2142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":311880162,"gmtCreate":1611774079656,"gmtModify":1703753742849,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","text":"$Sorrento Therapeutics Inc.(SRNE)$目标越来越近","images":[{"img":"https://static.tigerbbs.com/f4a43d04472d23638348204055645be2","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311880162","isVote":1,"tweetType":1,"viewCount":1909,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":313209913,"gmtCreate":1611716090432,"gmtModify":1703752582217,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","text":"$Sorrento Therapeutics Inc.(SRNE)$必须见$35","images":[{"img":"https://static.tigerbbs.com/6d826681b38c8ab6c93ba126180e62d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/313209913","isVote":1,"tweetType":1,"viewCount":1131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":304942649,"gmtCreate":1605126236481,"gmtModify":1703836347233,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这篇文章不错，转发给大家看","listText":"这篇文章不错，转发给大家看","text":"这篇文章不错，转发给大家看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/304942649","repostId":"2082718698","repostType":2,"repost":{"id":"2082718698","pubTimestamp":1604930400,"share":"https://www.laohu8.com/m/news/2082718698?lang=&edition=full","pubTime":"2020-11-09 22:00","market":"us","language":"en","title":"Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2082718698","media":"GlobeNewswire","summary":"IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild sympto","content":"<html><body><ul type=\"disc\">\n<li>IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers.</li>\n<li>These initial trials are expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization).</li>\n<li>Animal model data (golden Syrian hamsters infected with SARS-CoV-2) demonstrated a highly effective neutralizing profile.</li>\n<li>This antibody has been engineered for ultra-high potency, with an expected effective dose in humans to be much lower than current known antibodies being assessed by others in active trials, which would allow for a simple IV-push administration that is suitable in the outpatient setting.</li>\n<li>This antibody has been engineered and validated in preclinical studies to avoid antibody-dependent enhancement (ADE) to potentially increase the safety profile.</li>\n<li>Additional <em>in</em> <em>vitro </em>experiments demonstrated the complete virus neutralizing property of STI-2020 against the highly contagious D614G SARS-CoV-2 variant.</li>\n<li>Sorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.</li>\n</ul>\n<p>SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers.</p>\n<p>Sorrento has previously submitted an IND for COVI-GUARD™ (STI-1499), the parent antibody for COVI-AMG. That submission was cleared by the FDA in September. Sorrento has built on the knowledge from the prior IND requirements to file this new IND, including information and data about Sorrento’s affinity maturation process that further enhanced the potency of this antibody.</p>\n<p>As Sorrento previously announced, in preclinical studies, STI-2020 demonstrated a 100% neutralizing effect (both <em>in</em> <em>vitro</em> and <em>in vivo</em>) and at a very low dose prevented SARS-CoV-2 from infecting healthy cells and causing COVID-19-like disease in golden Syrian hamsters.</p>\n<p>The high potency of the antibody may potentially translate to more doses per bioreactor manufacturing run, lower cost per dose, and allow for rapid deployment and availability to patients. Sorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.</p>\n<p>In order to speed up development toward EUA submission, Sorrento is also planning on initiating dosing in a healthy population in order to rapidly generate safety and pharmacokinetic results.</p>\n<p>The STI-2020 antibody has been evaluated in preclinical studies against multiple strains of SARS-CoV-2, including the highly contagious D614G variant, the current dominant strain globally.</p>\n<p>The STI-2020 antibody has been engineered and demonstrated in preclinical studies to avoid ADE (antibody-dependent enhancement) which may be associated with the serious side effects of some other neutralizing antibodies and vaccines.</p>\n<p>More information about the phase 1 clinical trial can be found on www.clinicaltrials.gov (NCT# NCT04584697).</p>\n<p><strong>About Sorrento Therapeutics, Inc.  </strong><br/>Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (\"G-MAB™ library\"), clinical stage immuno-cellular therapies (\"CAR-T\", \"DAR-T™\"), antibody-drug conjugates (\"ADCs\"), and clinical stage oncolytic virus (\"Seprehvir<sup>®</sup>\"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.</p>\n<p>Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (\"RTX\"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.  SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.</p>\n<p>For more information, visit <u>www.sorrentotherapeutics.com</u></p>\n<p><strong>Forward-Looking Statements</strong><br/>This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potency and potential neutralizing profile of STI-2020 and the impact on SARS-CoV-2; the preclinical testing of STI-2020; the safety, pharmacokinetics and efficacy of STI-2020; the potential for STI-2020 to avoid antibody-dependent enhancement side effects; the expectation of the commencement of any pivotal trials for STI-2020; the potential receipt of an EUA for STI-2020 and expected timing for any receipt thereof; the expected availability of doses of STI-2020 and the timing thereof; the belief that the IND addresses all questions and recommendations from the FDA; the predictive value of the animal model used in preclinical studies; the proposed dosages in the phase 1 clinical trial; the potential potency of STI-2020; the expected effective dose in humans; the expected administration method of STI-2020; the potentially faster manufacturing speed, availability and potential lower cost for STI-2020; and Sorrento's potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical studies and seeking IND regulatory approval for STI-2020; conducting and receiving results of clinical trials for STI-2020; the clinical and commercial success of STI-2020 against preventing and treating SARS-CoV-2 virus infections; the viability and success of STI-2020 in anti-viral therapeutic areas, including coronaviruses; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.</p>\n<p><strong><u>Contact</u></strong><br/>Alexis Nahama, DVM (SVP Corporate Development)<br/>Email: <u>mediarelations@sorrentotherapeutics.com</u></p>\n<p>Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.<br/>G-MAB™, COVI-GUARD<sup>TM</sup>, COVI-AMG™, COVI-SHIELD™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™, ACE-MAB<sup>TM</sup>, COVI-DROPS<sup>TM</sup>, COVI-TRACK™, COVI-TRACE™, COVI-STIX™, and COVI-MOBILE™ are trademarks of Sorrento Therapeutics, Inc.</p>\n<p>ZTlido® is a trademark owned by Scilex Pharmaceuticals Inc.<br/>All other trademarks are the property of their respective owners. <br/>© 2020 Sorrento Therapeutics, Inc. All Rights Reserved.</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/304c722a-046e-41c0-94e8-d4603ebf6fd4\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-11-09 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sorrento-announces-fda-ind-filing-140000531.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers.\nThese initial trials are ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sorrento-announces-fda-ind-filing-140000531.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/PoKGHRAaEjCoeUQ7jQhw4g--~B/aD05MzM7dz0yNjU3O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/0La.lfx3M.BOH5N06.8hng--~B/aD05MzM7dz0yNjU3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/04f9f4e64b77331b9d9868e002a03144","relate_stocks":{"SRNE":"索伦托医疗"},"source_url":"https://finance.yahoo.com/news/sorrento-announces-fda-ind-filing-140000531.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2082718698","content_text":"IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers.\nThese initial trials are expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization).\nAnimal model data (golden Syrian hamsters infected with SARS-CoV-2) demonstrated a highly effective neutralizing profile.\nThis antibody has been engineered for ultra-high potency, with an expected effective dose in humans to be much lower than current known antibodies being assessed by others in active trials, which would allow for a simple IV-push administration that is suitable in the outpatient setting.\nThis antibody has been engineered and validated in preclinical studies to avoid antibody-dependent enhancement (ADE) to potentially increase the safety profile.\nAdditional in vitro experiments demonstrated the complete virus neutralizing property of STI-2020 against the highly contagious D614G SARS-CoV-2 variant.\nSorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.\n\nSAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers.\nSorrento has previously submitted an IND for COVI-GUARD™ (STI-1499), the parent antibody for COVI-AMG. That submission was cleared by the FDA in September. Sorrento has built on the knowledge from the prior IND requirements to file this new IND, including information and data about Sorrento’s affinity maturation process that further enhanced the potency of this antibody.\nAs Sorrento previously announced, in preclinical studies, STI-2020 demonstrated a 100% neutralizing effect (both in vitro and in vivo) and at a very low dose prevented SARS-CoV-2 from infecting healthy cells and causing COVID-19-like disease in golden Syrian hamsters.\nThe high potency of the antibody may potentially translate to more doses per bioreactor manufacturing run, lower cost per dose, and allow for rapid deployment and availability to patients. Sorrento has initiated cGMP manufacturing to produce 100,000 doses, expected to be available early next year, in anticipation of a potential EUA.\nIn order to speed up development toward EUA submission, Sorrento is also planning on initiating dosing in a healthy population in order to rapidly generate safety and pharmacokinetic results.\nThe STI-2020 antibody has been evaluated in preclinical studies against multiple strains of SARS-CoV-2, including the highly contagious D614G variant, the current dominant strain globally.\nThe STI-2020 antibody has been engineered and demonstrated in preclinical studies to avoid ADE (antibody-dependent enhancement) which may be associated with the serious side effects of some other neutralizing antibodies and vaccines.\nMore information about the phase 1 clinical trial can be found on www.clinicaltrials.gov (NCT# NCT04584697).\nAbout Sorrento Therapeutics, Inc.  Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (\"G-MAB™ library\"), clinical stage immuno-cellular therapies (\"CAR-T\", \"DAR-T™\"), antibody-drug conjugates (\"ADCs\"), and clinical stage oncolytic virus (\"Seprehvir®\"). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.\nSorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (\"RTX\"), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.  SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.\nFor more information, visit www.sorrentotherapeutics.com\nForward-Looking StatementsThis press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potency and potential neutralizing profile of STI-2020 and the impact on SARS-CoV-2; the preclinical testing of STI-2020; the safety, pharmacokinetics and efficacy of STI-2020; the potential for STI-2020 to avoid antibody-dependent enhancement side effects; the expectation of the commencement of any pivotal trials for STI-2020; the potential receipt of an EUA for STI-2020 and expected timing for any receipt thereof; the expected availability of doses of STI-2020 and the timing thereof; the belief that the IND addresses all questions and recommendations from the FDA; the predictive value of the animal model used in preclinical studies; the proposed dosages in the phase 1 clinical trial; the potential potency of STI-2020; the expected effective dose in humans; the expected administration method of STI-2020; the potentially faster manufacturing speed, availability and potential lower cost for STI-2020; and Sorrento's potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical studies and seeking IND regulatory approval for STI-2020; conducting and receiving results of clinical trials for STI-2020; the clinical and commercial success of STI-2020 against preventing and treating SARS-CoV-2 virus infections; the viability and success of STI-2020 in anti-viral therapeutic areas, including coronaviruses; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.\nContactAlexis Nahama, DVM (SVP Corporate Development)Email: mediarelations@sorrentotherapeutics.com\nSorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.G-MAB™, COVI-GUARDTM, COVI-AMG™, COVI-SHIELD™, COVIDTRAP™, T-VIVA-19™, COVI-MAB™, ACE-MABTM, COVI-DROPSTM, COVI-TRACK™, COVI-TRACE™, COVI-STIX™, and COVI-MOBILE™ are trademarks of Sorrento Therapeutics, Inc.\nZTlido® is a trademark owned by Scilex Pharmaceuticals Inc.All other trademarks are the property of their respective owners. © 2020 Sorrento Therapeutics, Inc. All Rights Reserved.","news_type":1},"isVote":1,"tweetType":1,"viewCount":705,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":308810328,"gmtCreate":1603922855464,"gmtModify":1703831264929,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"有够胆的就是接飞刀最好的时间了。","listText":"有够胆的就是接飞刀最好的时间了。","text":"有够胆的就是接飞刀最好的时间了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/308810328","isVote":1,"tweetType":1,"viewCount":1428,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":977967649,"gmtCreate":1601400234581,"gmtModify":1703824225490,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","text":"$Sorrento Therapeutics Inc.(SRNE)$这次上升的更稳","images":[{"img":"https://static.tigerbbs.com/ee5683f2e56fa34b6227645e925a80b5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/977967649","isVote":1,"tweetType":1,"viewCount":1526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":975454378,"gmtCreate":1600807585594,"gmtModify":1703822541962,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>看最后一个多小时的增量，你就应该知道上车或下车。","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>看最后一个多小时的增量，你就应该知道上车或下车。","text":"$Sorrento Therapeutics Inc.(SRNE)$看最后一个多小时的增量，你就应该知道上车或下车。","images":[{"img":"https://static.tigerbbs.com/3e10c19e147f0c6b79deb376c88043f1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/975454378","isVote":1,"tweetType":1,"viewCount":1322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":944486907,"gmtCreate":1597079392409,"gmtModify":1704214350249,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","text":"$Sorrento Therapeutics Inc.(SRNE)$终于站上18元","images":[{"img":"https://static.tigerbbs.com/0cc815413940745db4a4860346e74e46","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944486907","isVote":1,"tweetType":1,"viewCount":1085,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":944493484,"gmtCreate":1597071442748,"gmtModify":1704214309276,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","text":"$Sorrento Therapeutics Inc.(SRNE)$我也成绩不错","images":[{"img":"https://static.tigerbbs.com/d1c25d50891643ebcf0c1815243ee16b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944493484","isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":952471311,"gmtCreate":1592208851733,"gmtModify":1704198251913,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"期待行情大反弹。","listText":"期待行情大反弹。","text":"期待行情大反弹。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952471311","isVote":1,"tweetType":1,"viewCount":782,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952401357,"gmtCreate":1592122184879,"gmtModify":1704198127043,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"燃石医学开涨43.64%，后面的行情会怎么走呢？&nbsp;&nbsp;","listText":"燃石医学开涨43.64%，后面的行情会怎么走呢？&nbsp;&nbsp;","text":"燃石医学开涨43.64%，后面的行情会怎么走呢？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952401357","isVote":1,"tweetType":1,"viewCount":610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952568771,"gmtCreate":1592028293893,"gmtModify":1704198062641,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","listText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","text":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952568771","isVote":1,"tweetType":1,"viewCount":834,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952851902,"gmtCreate":1591944015406,"gmtModify":1704197676916,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"这篇文章不错，转发给大家看","listText":"这篇文章不错，转发给大家看","text":"这篇文章不错，转发给大家看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952851902","repostId":"952993441","repostType":1,"repost":{"id":952993441,"gmtCreate":1591835131983,"gmtModify":1704197176907,"author":{"id":"3540880674211350","authorId":"3540880674211350","name":"edward28","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"很多投资者近两天没有把握好盈利，将挣到手的钱又全部做善事了。","listText":"很多投资者近两天没有把握好盈利，将挣到手的钱又全部做善事了。","text":"很多投资者近两天没有把握好盈利，将挣到手的钱又全部做善事了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952993441","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":721,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952828396,"gmtCreate":1591938857515,"gmtModify":1704197664876,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"心态不好真的别进股市，这过山车的波动一段人怎可承受呀。","listText":"心态不好真的别进股市，这过山车的波动一段人怎可承受呀。","text":"心态不好真的别进股市，这过山车的波动一段人怎可承受呀。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952828396","isVote":1,"tweetType":1,"viewCount":1224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952953640,"gmtCreate":1591857967180,"gmtModify":1704197264337,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"油股调整到位","listText":"油股调整到位","text":"油股调整到位","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/952953640","isVote":1,"tweetType":1,"viewCount":962,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956426756,"gmtCreate":1591775561275,"gmtModify":1704196838756,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"油股调整到位了吧","listText":"油股调整到位了吧","text":"油股调整到位了吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956426756","isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956946787,"gmtCreate":1591511304049,"gmtModify":1704195899483,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"涨的差不多了，目前熊市已是不可能了，但回调是有必要的，小心手上的盈利吧。","listText":"涨的差不多了，目前熊市已是不可能了，但回调是有必要的，小心手上的盈利吧。","text":"涨的差不多了，目前熊市已是不可能了，但回调是有必要的，小心手上的盈利吧。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956946787","isVote":1,"tweetType":1,"viewCount":468,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":313209913,"gmtCreate":1611716090432,"gmtModify":1703752582217,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>必须见$35","text":"$Sorrento Therapeutics Inc.(SRNE)$必须见$35","images":[{"img":"https://static.tigerbbs.com/6d826681b38c8ab6c93ba126180e62d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/313209913","isVote":1,"tweetType":1,"viewCount":1131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":923147816,"gmtCreate":1585808588435,"gmtModify":1704359028188,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CCL\">$嘉年华邮轮(CCL)$</a>买入ccl游轮股是一次高风险又是高回报的大机遇","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/CCL\">$嘉年华邮轮(CCL)$</a>买入ccl游轮股是一次高风险又是高回报的大机遇","text":"$嘉年华邮轮(CCL)$买入ccl游轮股是一次高风险又是高回报的大机遇","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/923147816","isVote":1,"tweetType":1,"viewCount":941,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":977967649,"gmtCreate":1601400234581,"gmtModify":1703824225490,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>这次上升的更稳","text":"$Sorrento Therapeutics Inc.(SRNE)$这次上升的更稳","images":[{"img":"https://static.tigerbbs.com/ee5683f2e56fa34b6227645e925a80b5","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/977967649","isVote":1,"tweetType":1,"viewCount":1526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":927560639,"gmtCreate":1588934295321,"gmtModify":1704178947295,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"今天油价的利好能抵挡历史性最差的非农吗？大家有什么看法，我认为基本大利空已不具备，今晚市场会走好。","listText":"今天油价的利好能抵挡历史性最差的非农吗？大家有什么看法，我认为基本大利空已不具备，今晚市场会走好。","text":"今天油价的利好能抵挡历史性最差的非农吗？大家有什么看法，我认为基本大利空已不具备，今晚市场会走好。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/927560639","isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":928899061,"gmtCreate":1586587140753,"gmtModify":1704361739836,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"下周油股应该看多","listText":"下周油股应该看多","text":"下周油股应该看多","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/928899061","isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":921740797,"gmtCreate":1586399467719,"gmtModify":1704361168193,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"AAON艾伦建材可留意","listText":"AAON艾伦建材可留意","text":"AAON艾伦建材可留意","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/921740797","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168615926,"gmtCreate":1623973821065,"gmtModify":1623973821065,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>怎么看","text":"$Sorrento Therapeutics Inc.(SRNE)$怎么看","images":[{"img":"https://static.tigerbbs.com/99037d09bdee63c58835fa40503ef6c3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168615926","isVote":1,"tweetType":1,"viewCount":2188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":311880162,"gmtCreate":1611774079656,"gmtModify":1703753742849,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>目标越来越近","text":"$Sorrento Therapeutics Inc.(SRNE)$目标越来越近","images":[{"img":"https://static.tigerbbs.com/f4a43d04472d23638348204055645be2","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/311880162","isVote":1,"tweetType":1,"viewCount":1909,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":944486907,"gmtCreate":1597079392409,"gmtModify":1704214350249,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>终于站上18元","text":"$Sorrento Therapeutics Inc.(SRNE)$终于站上18元","images":[{"img":"https://static.tigerbbs.com/0cc815413940745db4a4860346e74e46","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944486907","isVote":1,"tweetType":1,"viewCount":1085,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":952401357,"gmtCreate":1592122184879,"gmtModify":1704198127043,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"燃石医学开涨43.64%，后面的行情会怎么走呢？&nbsp;&nbsp;","listText":"燃石医学开涨43.64%，后面的行情会怎么走呢？&nbsp;&nbsp;","text":"燃石医学开涨43.64%，后面的行情会怎么走呢？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952401357","isVote":1,"tweetType":1,"viewCount":610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":952568771,"gmtCreate":1592028293893,"gmtModify":1704198062641,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","listText":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","text":"惊心动魄的一周在最后半小时给了往后行情一根定海神针。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/952568771","isVote":1,"tweetType":1,"viewCount":834,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":953630981,"gmtCreate":1590302537443,"gmtModify":1704192298574,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"港板国安法对全球影响不容勿视","listText":"港板国安法对全球影响不容勿视","text":"港板国安法对全球影响不容勿视","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/953630981","isVote":1,"tweetType":1,"viewCount":858,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":950886147,"gmtCreate":1589329957289,"gmtModify":1704179884503,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"今年就是各种耍嘴皮。","listText":"今年就是各种耍嘴皮。","text":"今年就是各种耍嘴皮。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/950886147","repostId":"2035604431","repostType":4,"repost":{"id":"2035604431","pubTimestamp":1589327885,"share":"https://www.laohu8.com/m/news/2035604431?lang=&edition=full","pubTime":"2020-05-13 07:58","market":"us","language":"zh","title":"传美国又向中国芯片动手，对中芯、华虹等启动无限追溯","url":"https://stock-news.laohu8.com/highlight/detail?id=2035604431","media":"证券时报","summary":"随着5月15日美国对华为临时许可证限期将到期，市场有关美国将加大对国内半导体代工厂限制的禁令声再起。\n不过，中信证券当晚立即公开对媒体表示，美国对华半导体代工厂禁令系谣传。\n中信证券电子组同时表示，一","content":"<p>随着5月15日美国对华为临时许可证限期将到期，市场有关美国将加大对国内半导体代工厂限制的禁令声再起。</p>\n<p>不过，<a href=\"https://laohu8.com/S/600030\">中信证券</a>当晚立即公开对媒体表示，美国对华半导体代工厂禁令系谣传。</p>\n<p><a href=\"https://laohu8.com/S/06030\">中信证券</a>电子组同时表示，一则未经证实的消息广泛传播，显示了中美互信消失之后的杯弓蛇影。不论消息是否属实，都会加速半导体设备、材料、制造领域的国产化替代。</p>\n<p>传美国将对华半导体代工厂启动“无限追溯”机制</p>\n<p>5月12日晚，一条关于半导体的新闻在网络广泛传播。据《科创板日报》报道，记者12日晚间从供应链获悉，美国半导体设备制造商LAM(泛林半导体)和AMAT(应材公司)等公司发出信函，要求中国国内从事军民融合或为军品供应集成电路的企业(如<a href=\"https://laohu8.com/S/00981\">中芯国际</a>和<a href=\"https://laohu8.com/S/01347\">华虹半导体</a>等)，不得用美国清单厂商半导体设备代工生产军用集成电路，同时“无限追溯”机制生效。</p>\n<p><img src=\"https://static.tigerbbs.com/bc19a72b5f6d2da86cd34893c813e183\" tg-width=\"415\" tg-height=\"420\"></p>\n<p>据了解，美国是公认的世界第一大半导体产业强国，就半导体企业销售额来说，美国独占全球50%以上的市场份额。全球10大芯片企业中，美国企业占6家，其余4家企业都来自亚洲，包括<a href=\"https://laohu8.com/S/SSNLF\">三星电子</a>、<a href=\"https://laohu8.com/S/TSM\">台积电</a>、海力士和海思。正是由于有强大的实力做后盾，美国才能轻易地对其它国家实施制裁，并且将美国的法律延伸到世界各国。因此美国可以要求其它国家向华为出口芯片时，必需获得美国的出口许可证。</p>\n<p>企业方面，此次涉及的<a href=\"https://laohu8.com/S/AMAT\">应用材料</a>、泛林在全球半导体设备市场份额分别占比约17%、13%，为全球第一、第四大设备厂商，在沉积、刻蚀、离子注入、CMP、匀胶显影等领域技术领先，尤其先进制程设备较难由非美厂商替代。</p>\n<p>据媒体报道，应用材料（AMAT）、泛林集团（LAM）要求收函单位承诺或确认不会将他们的产品、技术、软件用于“军事最终用途military end use”，函件中表示，军事最终用途的定义扩展到军用物品或和维护相关包括运行operation、安装installation、保养maintenance、维修repair、大修overhaul、翻新refurbishing。</p>\n<p>若此次禁令属实，可谓美国对华出口的管制升级。上月底的4月28日，美国商务部下属工业和安全局刚刚发布修订的《出口管理规则，规则旨在扩大用于对中国、俄罗斯和委内瑞拉境内的军事用途或军事用户的物品出口限制。此规则将“军事最终用户military end users”的范围扩大“军事最终用途military end use”，对此类情况加强了许可要求和审查政策适用的项目清单。就是美国可以认定该物品的最终用途，美国说是军用就是军用。据悉，此次美政府表示将施加对华出口新限制，包括民用飞机零部件和半导体生产设备等。</p>\n<p>谣言？这些个股已大涨！</p>\n<p>此次美国将对华半导体代工厂启动“无限追溯”机制的消息发布后，中信证券电子组立即通过媒体发声称，美国对华半导体代工厂禁令系谣传。</p>\n<p>据<a href=\"https://laohu8.com/S/SINA\">新浪</a>财经报道，上述消息发布后，中信证券电子组立即询问相关上市公司，中芯国际、华虹半导体方面表示未收到类似函件。此外，中信证券还表示已与消息来源财联社（科创板日报）确认，对方表示相关描述不准确，中芯国际和华虹半导体和此事件无关，并未收到类似信函，致歉并确认随后会修改相关稿件。</p>\n<p>中信证券电子组称，应用材料（AMAT）、泛林（LAM）是中芯国际和华虹半导体的重要设备供应商，供应商无缘由发函给下游客户从商业角度考量逻辑不合理，除非美国相关部门授意，真实性需进一步确认消息来源。如中芯国际在3月公告就披露了采购自泛林（LAM）、应用材料、东京电子的设备订单，分别为6亿美元、5.4亿美元、5.5亿美元，采购金额较大。</p>\n<p>不过，中信证券电子组表示，美政府近几个月以来持续对华加大半导体领域相关限制措施，一则尚未经证实的消息广泛传播，显示了中美互信消失之后的杯弓蛇影。不论消息是否属实，都会加速半导体设备、材料、制造领域的国产化替代。</p>\n<p>信达证券电子行业首席分析师方竞也表示，本次发函具体如何执行，美国半导体设备公司均未有定论；大家关心的SMIC和华虹没有任何军工业务。短期对市场有影响，但长期有利于半导体设备的自主可控。</p>\n<p>芯思想研究院认为，可能会将目前国内晶圆制造厂购买美国设备不需要申请出口许可的状态改变，要回到一次一申请的状态。</p>\n<p>有意思的是，此次半导体禁令发布前，5月12日，芯片股异动，<a href=\"https://laohu8.com/S/002049\">紫光国微</a>放量涨停，股价逼近历史高点，收报68.53元，成交额35.68亿元。盘后数据显示，深股通占据了买二、卖一的位置，买入2.09亿元并卖出1亿元，占当日成交总额的3.05%。<a href=\"https://laohu8.com/S/601788\">光大证券</a>北京金融大街买入2.41亿元，<a href=\"https://laohu8.com/S/03908\">中金公司</a>南京太平南路买入4080万元。</p>\n<p><img src=\"https://static.tigerbbs.com/19bd588977a6a538bbdf145e7aac8696\" tg-width=\"367\" tg-height=\"196\"></p>\n<p>华为一手机芯片全部国产化，郭台铭：支持国产化！</p>\n<p>美国对华半导体步步紧逼之际，华为一款手机芯片，近日最新实现了全部国产化。</p>\n<p>在中芯国际成立20周年之际，在一款发放给员工的华为手机中，“SMIC20”代工的logo出现在了手机的背面。这意味着，中芯国际14纳米FinFET代工的移动芯片，真正在手机处理器上实现了规模化量产和商业化。</p>\n<p>“此前中芯国际14nm主要跑华为的RF Transceiver芯片，但在麒麟710A处理器突破后，产能利用率有了大幅提升。”信达证券电子行业首席分析师方竞表示，虽然麒麟710A是两年前发售的老处理器，但这是一次新的突破。</p>\n<p>据了解，从芯片设计、代工到封装测试环节，这款芯片首次实现全部国产化，意味着国产14nm工艺“从0到1的突破”。</p>\n<p>另一方面，从Mate30开始，华为国内供应链厂商占比越来越高。</p>\n<p>近日，富士康创始人郭台铭也再次表示：“将会支持国产芯片、国产自主操作系统的自主研发，因为自研芯片、自研操作系统对于任何一家科技企业，尤其是对于中国企业而言，都是非常重要，因为唯有掌握核心技术，才能够让公司更好的发展。”</p>\n<p>诺德基金基金经理刘先政认为，随着国内新建的晶圆厂陆续实现量产，全球半导体产业链逐渐向我国转移，国内销售的芯片的国产占比有望在2023年提升至20%。在产能向国内转移的过程中，国内半导体设备、材料、封测等厂商都有望受益，而在国内晶圆厂、华为等公司的支持下，半导体产业国产化率将提升，国内半导体行业有望继续加速成长。</p>\n<p>目前，华为海思是国内芯片设计领域的领头羊，销售额远超国内其他设计公司，在国内手机芯片市场市占率达到第一。从今年一季度国内手机芯片出货量来看，华为海思处理器市场份额高达43.9%，<a href=\"https://laohu8.com/S/QCOM\">高通</a>骁龙芯片市场份额32.8%，联发科、<a href=\"https://laohu8.com/S/AAPL\">苹果</a>分别为13.1%、8.5%。</p>\n<p>值得一提的是，2019年5月，美国商务部以国家安全为由，将华为纳入实体清单，不过，该部门随后多次延长临时许可限制，今年3月，美国政府表示，将延长华为临时许可证到5月15日，允许美国企业与华为之间开展业务，这意味着美国对华为临时许可证限期将至，但目前仍未有最新消息。</p>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>传美国又向中国芯片动手，对中芯、华虹等启动无限追溯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n传美国又向中国芯片动手，对中芯、华虹等启动无限追溯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-05-13 07:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/y/2020-05-13/doc-iircuyvi2787982.shtml><strong>证券时报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>随着5月15日美国对华为临时许可证限期将到期，市场有关美国将加大对国内半导体代工厂限制的禁令声再起。\n不过，中信证券当晚立即公开对媒体表示，美国对华半导体代工厂禁令系谣传。\n中信证券电子组同时表示，一则未经证实的消息广泛传播，显示了中美互信消失之后的杯弓蛇影。不论消息是否属实，都会加速半导体设备、材料、制造领域的国产化替代。\n传美国将对华半导体代工厂启动“无限追溯”机制\n5月12日晚，一条关于...</p>\n\n<a href=\"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/y/2020-05-13/doc-iircuyvi2787982.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8c95dc9b62af63b498dce2238fb18ba3","relate_stocks":{},"source_url":"http://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/y/2020-05-13/doc-iircuyvi2787982.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2035604431","content_text":"随着5月15日美国对华为临时许可证限期将到期，市场有关美国将加大对国内半导体代工厂限制的禁令声再起。\n不过，中信证券当晚立即公开对媒体表示，美国对华半导体代工厂禁令系谣传。\n中信证券电子组同时表示，一则未经证实的消息广泛传播，显示了中美互信消失之后的杯弓蛇影。不论消息是否属实，都会加速半导体设备、材料、制造领域的国产化替代。\n传美国将对华半导体代工厂启动“无限追溯”机制\n5月12日晚，一条关于半导体的新闻在网络广泛传播。据《科创板日报》报道，记者12日晚间从供应链获悉，美国半导体设备制造商LAM(泛林半导体)和AMAT(应材公司)等公司发出信函，要求中国国内从事军民融合或为军品供应集成电路的企业(如中芯国际和华虹半导体等)，不得用美国清单厂商半导体设备代工生产军用集成电路，同时“无限追溯”机制生效。\n\n据了解，美国是公认的世界第一大半导体产业强国，就半导体企业销售额来说，美国独占全球50%以上的市场份额。全球10大芯片企业中，美国企业占6家，其余4家企业都来自亚洲，包括三星电子、台积电、海力士和海思。正是由于有强大的实力做后盾，美国才能轻易地对其它国家实施制裁，并且将美国的法律延伸到世界各国。因此美国可以要求其它国家向华为出口芯片时，必需获得美国的出口许可证。\n企业方面，此次涉及的应用材料、泛林在全球半导体设备市场份额分别占比约17%、13%，为全球第一、第四大设备厂商，在沉积、刻蚀、离子注入、CMP、匀胶显影等领域技术领先，尤其先进制程设备较难由非美厂商替代。\n据媒体报道，应用材料（AMAT）、泛林集团（LAM）要求收函单位承诺或确认不会将他们的产品、技术、软件用于“军事最终用途military end use”，函件中表示，军事最终用途的定义扩展到军用物品或和维护相关包括运行operation、安装installation、保养maintenance、维修repair、大修overhaul、翻新refurbishing。\n若此次禁令属实，可谓美国对华出口的管制升级。上月底的4月28日，美国商务部下属工业和安全局刚刚发布修订的《出口管理规则，规则旨在扩大用于对中国、俄罗斯和委内瑞拉境内的军事用途或军事用户的物品出口限制。此规则将“军事最终用户military end users”的范围扩大“军事最终用途military end use”，对此类情况加强了许可要求和审查政策适用的项目清单。就是美国可以认定该物品的最终用途，美国说是军用就是军用。据悉，此次美政府表示将施加对华出口新限制，包括民用飞机零部件和半导体生产设备等。\n谣言？这些个股已大涨！\n此次美国将对华半导体代工厂启动“无限追溯”机制的消息发布后，中信证券电子组立即通过媒体发声称，美国对华半导体代工厂禁令系谣传。\n据新浪财经报道，上述消息发布后，中信证券电子组立即询问相关上市公司，中芯国际、华虹半导体方面表示未收到类似函件。此外，中信证券还表示已与消息来源财联社（科创板日报）确认，对方表示相关描述不准确，中芯国际和华虹半导体和此事件无关，并未收到类似信函，致歉并确认随后会修改相关稿件。\n中信证券电子组称，应用材料（AMAT）、泛林（LAM）是中芯国际和华虹半导体的重要设备供应商，供应商无缘由发函给下游客户从商业角度考量逻辑不合理，除非美国相关部门授意，真实性需进一步确认消息来源。如中芯国际在3月公告就披露了采购自泛林（LAM）、应用材料、东京电子的设备订单，分别为6亿美元、5.4亿美元、5.5亿美元，采购金额较大。\n不过，中信证券电子组表示，美政府近几个月以来持续对华加大半导体领域相关限制措施，一则尚未经证实的消息广泛传播，显示了中美互信消失之后的杯弓蛇影。不论消息是否属实，都会加速半导体设备、材料、制造领域的国产化替代。\n信达证券电子行业首席分析师方竞也表示，本次发函具体如何执行，美国半导体设备公司均未有定论；大家关心的SMIC和华虹没有任何军工业务。短期对市场有影响，但长期有利于半导体设备的自主可控。\n芯思想研究院认为，可能会将目前国内晶圆制造厂购买美国设备不需要申请出口许可的状态改变，要回到一次一申请的状态。\n有意思的是，此次半导体禁令发布前，5月12日，芯片股异动，紫光国微放量涨停，股价逼近历史高点，收报68.53元，成交额35.68亿元。盘后数据显示，深股通占据了买二、卖一的位置，买入2.09亿元并卖出1亿元，占当日成交总额的3.05%。光大证券北京金融大街买入2.41亿元，中金公司南京太平南路买入4080万元。\n\n华为一手机芯片全部国产化，郭台铭：支持国产化！\n美国对华半导体步步紧逼之际，华为一款手机芯片，近日最新实现了全部国产化。\n在中芯国际成立20周年之际，在一款发放给员工的华为手机中，“SMIC20”代工的logo出现在了手机的背面。这意味着，中芯国际14纳米FinFET代工的移动芯片，真正在手机处理器上实现了规模化量产和商业化。\n“此前中芯国际14nm主要跑华为的RF Transceiver芯片，但在麒麟710A处理器突破后，产能利用率有了大幅提升。”信达证券电子行业首席分析师方竞表示，虽然麒麟710A是两年前发售的老处理器，但这是一次新的突破。\n据了解，从芯片设计、代工到封装测试环节，这款芯片首次实现全部国产化，意味着国产14nm工艺“从0到1的突破”。\n另一方面，从Mate30开始，华为国内供应链厂商占比越来越高。\n近日，富士康创始人郭台铭也再次表示：“将会支持国产芯片、国产自主操作系统的自主研发，因为自研芯片、自研操作系统对于任何一家科技企业，尤其是对于中国企业而言，都是非常重要，因为唯有掌握核心技术，才能够让公司更好的发展。”\n诺德基金基金经理刘先政认为，随着国内新建的晶圆厂陆续实现量产，全球半导体产业链逐渐向我国转移，国内销售的芯片的国产占比有望在2023年提升至20%。在产能向国内转移的过程中，国内半导体设备、材料、封测等厂商都有望受益，而在国内晶圆厂、华为等公司的支持下，半导体产业国产化率将提升，国内半导体行业有望继续加速成长。\n目前，华为海思是国内芯片设计领域的领头羊，销售额远超国内其他设计公司，在国内手机芯片市场市占率达到第一。从今年一季度国内手机芯片出货量来看，华为海思处理器市场份额高达43.9%，高通骁龙芯片市场份额32.8%，联发科、苹果分别为13.1%、8.5%。\n值得一提的是，2019年5月，美国商务部以国家安全为由，将华为纳入实体清单，不过，该部门随后多次延长临时许可限制，今年3月，美国政府表示，将延长华为临时许可证到5月15日，允许美国企业与华为之间开展业务，这意味着美国对华为临时许可证限期将至，但目前仍未有最新消息。","news_type":1},"isVote":1,"tweetType":1,"viewCount":412,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":950114726,"gmtCreate":1589289328665,"gmtModify":1704179740210,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$</a>这股估计得百元才能消停","listText":"<a href=\"https://laohu8.com/S/NVAX\">$诺瓦瓦克斯医药(NVAX)$</a>这股估计得百元才能消停","text":"$诺瓦瓦克斯医药(NVAX)$这股估计得百元才能消停","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/950114726","isVote":1,"tweetType":1,"viewCount":188,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":950010367,"gmtCreate":1589149393860,"gmtModify":1704179314863,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"台积电会在五月创新高吗？我认为机会有八成，你认为呢？","listText":"台积电会在五月创新高吗？我认为机会有八成，你认为呢？","text":"台积电会在五月创新高吗？我认为机会有八成，你认为呢？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/950010367","isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":927746822,"gmtCreate":1589065992966,"gmtModify":1704179253257,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"FB应该有一波行情启动","listText":"FB应该有一波行情启动","text":"FB应该有一波行情启动","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/927746822","repostId":"1166051331","repostType":4,"repost":{"id":"1166051331","pubTimestamp":1589015335,"share":"https://www.laohu8.com/m/news/1166051331?lang=&edition=full","pubTime":"2020-05-09 17:08","market":"us","language":"zh","title":"Facebook董事会大洗牌，看小扎如何控制社交帝国","url":"https://stock-news.laohu8.com/highlight/detail?id=1166051331","media":"硅谷封面","summary":"编者按：Facebook首席执行官马克 扎克伯格(Mark Zuckerberg)相对低调，长期以来总是依靠首席运营官桑德伯格来处理政策和运营问题，依靠首席产品官考克斯来监管平台的许多重大变化。但随着","content":"<p><b>编者按：</b><a href=\"https://laohu8.com/S/FB\">Facebook</a>首席执行官马克 扎克伯格(Mark Zuckerberg)相对低调，长期以来总是依靠首席运营官桑德伯格来处理政策和运营问题，依靠首席产品官考克斯来监管平台的许多重大变化。但随着Facebook在虚假信息传播、用户数据监管失之于宽、公司竞争方式等诸多方面频频遭受非议，这位35岁的社交媒体大亨开始走上前台，通过董事会大洗牌获得对公司管理的更多控制权，并试图通过公司在应对疫情中的一系列高调举措扭转公众印象。</p>\n<p><img src=\"https://static.tigerbbs.com/24496c8880d643fe0a2edf0bde6d0c1e\"></p>\n<p><b>以下为文章正文：</b></p>\n<p>去年12月，社交媒体公司Facebook的高管们齐聚在马克 扎克伯格(Mark Zuckerberg)位于夏威夷考艾岛(Kauai)的海滨别墅。在这座占地700多英亩的私人宅邸内，扎克伯格主持召开了一次非同寻常的董事会，讨论在公司经历多年动荡之后该如何调整运营方向。</p>\n<p>据知情人士透露，会上确定的一些变化让很多人始料未及。</p>\n<p>几个月后Facebook宣布两位董事离职，并将扎克伯格的一位老朋友吸收进公司董事会。过去两年中，扎克伯格为巩固自身决策权而采取了一系列行动，这些举措也标志着其行动达到了高峰。扎克伯格还指导Facebook在应对新型冠状病毒疫情方面开展了一系列高调活动，将自己置于媒体的聚光灯下。</p>\n<p>其带来的结果是，这位Facebook首席执行官和董事长比过去几年更积极、更明显地担起自己在管理公司方面的职责。</p>\n<p>在此之前的三年多时间中，Facebook一直因在虚假信息传播、用户数据监管失之于宽、公司竞争方式等诸多方面存在的问题而引发各种争议。目前还不能确定，扎克伯格对Facebook的重新定位以及自己在公司高层的角色转变，是否能给Facebook的声誉带来持久转变。</p>\n<p>长期任职的董事以及过去两年中几位长期副手的离职，意味着扎克伯格正在没有关键顾问、或许没人帮忙发现潜在陷阱的情况度过这一时期。</p>\n<p>扎克伯格拒绝置评。Facebook的一位发言人说：“Facebook的根本使命是建立联系，而联系从来没有像现在这样如此重要。”</p>\n<p>从某种程度上而言，扎克伯格是按照他在2017年2月发布的近6000字宣言来定位Facebook。在此之中他设想Facebook是“社会基础设施”，可以帮助解决疾病等全球问题。然而，这个雄心勃勃的愿景却被外部势力操纵平台、剑桥分析公司不当访问用户数据等嘈杂声音掩盖了。</p>\n<p>不少联邦以及州层面的政府机构一直在调查Facebook。美国联邦贸易委员会（FCC）于2018年开始调查公司的用户数据问题，去年7月与Facebook达成了创纪录的50亿美元和解协议。</p>\n<p><img src=\"https://static.tigerbbs.com/bc43af59629d1d16d120237fe83b2e41\"><i>Facebook应用</i></p>\n<p>长期以来，扎克伯格一直依靠首席运营官、事实上的副手雪莉·桑德伯格(Sheryl Sandberg)来处理政策和运营问题，依靠首席产品官、老朋友克里斯·考克斯(Chris Cox)来监管平台的许多重大调整和变化。</p>\n<p>扎克伯格在2018年担负起了公司战时领导人的角色，不仅常常需要迅速采取行动，有时还需要单方作出决策。他宣布了一系列将Facebook引向新方向的产品，从2019年3月发布的声明开始，公司着重强调私有加密信息，而不是出名的公开信息。</p>\n<p>扎克伯格说，新的关注重点将使Facebook更像家中客厅而非城镇广场。这也让扎克伯格在Instagram和WhatsApp上获得了新的管理权，此前他曾承诺要独立运营这两家公司。</p>\n<p>消息公布后不久，曾被视为扎克伯格潜在继任者的考克斯出人意料辞职。此时距离考克斯入职Facebook已经有13年的时间。</p>\n<p>据知情人士透露，考克斯担心，向加密技术的转变会妨碍对恐怖主义和贩卖儿童等犯罪活动的调查。</p>\n<p>去年4月，Facebook披露两名长期独立董事将离开董事会。他们分别是Netflix 首席执行官里德·哈斯廷斯(Reed Hastings)和前投资银行家、克林顿政府官员厄斯金·鲍尔斯(Erskine Bowles)。</p>\n<p>据一位直接了解鲍尔斯的人士透露，鲍尔斯离职后曾私下批评Facebook的领导层没有听取他在政府政策方面的建议，而这正是鲍尔斯的专长所在。鲍尔斯拒绝置评。哈斯廷斯的发言人也没有回复置评请求。</p>\n<p>去年10月Facebook表示，自2015年6月起担任首席独立董事的苏珊 德斯蒙德-赫尔曼(Susan Desmond-Hellmann)将离开董事会。Facebook援引德斯蒙德-赫尔曼的话说，其离职是出于身体健康和家庭原因。一位知情人士则说，德斯蒙德-赫尔曼私下向一些人表示，自己离开Facebook的部分原因是她认为董事会运作不正常，而且Facebook管理层不会考虑董事会的意见。</p>\n<p>今年4月份，德斯蒙德-赫尔曼加入了制药巨头辉瑞公司的董事会。记者上周联系到德斯蒙德-赫尔曼请她置评有关离职Facebook的问题。她说Facebook的新闻稿是准确的，并对相关人士的描述提出了质疑。</p>\n<p><b>掌权</b></p>\n<p>据知情人士透露，扎克伯格去年12月在位于夏威夷的私人宅邸主持召开董事会会议，希望借助当地优美环境缓和一下紧张局势。</p>\n<p>会上董事和高管们审视了公司所面临的越来越多监管问题，包括Facebook将如何应对涉及要求复杂的美国联邦贸易委员会和解协议。这些人士说，他们讨论了公司战略、文化和治理方面的诸多问题。其中一位知情人士说，一些人在结束会议时感觉情况可能会好转。</p>\n<p>然而在下个月的财报电话会议上，扎克伯格似乎已经开始从道歉作出改变。他说，Facebook过去没有明确表达过自己的观点，“因为我们担心冒犯别人”。“我下一个十年的目标不是让人喜欢，而是让人理解。”</p>\n<p>扎克伯格需要赢得更多的董事会支持。知情人士称，他一直与任职时间最长的董事之一、风险投资大师马克 安德森(Marc Andreessen)意见不合。其中一名知情人士说，在Facebook努力遵守美国联邦贸易委员会和解协议的过程中，两人“各执一词、互不相让”。</p>\n<p>知情人士说，安德森向一些人表露出自己对Facebook是否有能力并愿意遵守这些条款感到失望的态度，并考虑离开董事会。安德森-霍洛维茨基金的发言人拒绝置评。</p>\n<p>Facebook发言人说，安德森从未怀疑过公司遵守和解协议的能力或承诺。</p>\n<p>去年春天，<a href=\"https://laohu8.com/S/PYPL\">PayPal</a>高管佩吉 阿尔福德(Peggy Alford)加入了Facebook董事会。阿尔福德曾在扎克伯格手下担任基金会“陈-扎克伯格行动”(Chan Zuckerberg Initiative)的首席财务官。今年2月份，扎克伯格在董事会获得了更多支持，其老朋友、云软件公司Dropbox首席执行官德鲁 休斯顿(Drew Houston)也加入进来。</p>\n<p>休斯顿的发言人拒绝置评。阿尔福德没有回复记者的置评请求。</p>\n<p>当新型冠状病毒疫情在美国蔓延开来时，扎克伯格迅速动员起整个Facebook。3月2日，他召集公司业务和产品部门的高级代表开会讨论应对措施。</p>\n<p>知情人士说，扎克伯格和其他高层领导人认为Facebook有机会发挥重要作用。参与讨论的一名人士表示，他们要求高管们想出一个“有助于改变公众对Facebook看法”的好主意。</p>\n<p>其中一个想法是开展一场声势浩大的广告宣传活动，向Facebook用户打出这样的口号：“如果我们能找到彼此，我们就永远不会迷路。”</p>\n<p>公司发言人则反驳了扎克伯格曾鼓励参会代表们将Facebook反应视为一次公关良机的说辞。这位发言人表示：“任何声誉提升都将是这项工作的副产品，而不是驱动因素。”</p>\n<p>3月初的一个周末，20名高级管理人员又在扎克伯格位于加州帕洛阿尔托(Palo Alto)的住所内参与了一个名为新型冠状病毒信息中心(coronavirus information hub)的项目，其中包括诸如提醒保持社交距离等功能。几天之内这个项目就上线了。</p>\n<p><b>调整</b></p>\n<p>3月中旬，Facebook宣布<a href=\"https://laohu8.com/S/AXP\">美国运通</a>(American <a href=\"https://laohu8.com/S/EXPR\">Express</a>)前首席执行官肯尼斯 切诺特(Kenneth Chenault)将离开董事会。</p>\n<p>他和扎克伯格一度关系密切。据一名熟悉二人关系的人士透露，在2018年2月加入董事会之前，扎克伯格有段时间每周都会给切诺特打电话征求意见，把他当作懂得如何管理大型机构的“善良叔叔”。</p>\n<p><img src=\"https://static.tigerbbs.com/29939166c6d49fe6c67f294c0dc3e4c0\"><i>Facebook董事会成员的调整变化</i></p>\n<p>但现在切诺特已经幡然醒悟。据知情人士透露，在加入Facebook后不久，切诺特就试图创建一个专门研究Facebook问题的外部咨询小组，并绕开扎克伯格直接向董事会提交报告。结果董事会里的其他人提出反对意见，这个主意最终落空了。</p>\n<p><img src=\"https://static.tigerbbs.com/c9c1cb28f28f06a7ad9d0b0cf7863d2b\"><i>美国运通前首席执行官肯尼斯 切诺特(Kenneth Chenault)</i></p>\n<p>在Facebook宣布离职的声明中，切诺特说自己之所以离职，是因为能加入<a href=\"https://laohu8.com/S/BRK.A\">伯克希尔</a>哈撒韦公司董事会，这一机会千载难逢。</p>\n<p>大约两周后，Facebook表示齐恩茨也将离开董事会，腾出更多时间处理自家业务。知情人士说，数月来切诺特和齐恩茨都对整个管理层以及公司处理错误信息的方式感到不满。</p>\n<p>今年3月份，Facebook任命前美国副财长、商人罗伯特·M·金米特(Robert M. Kimmitt)为首席独立董事。麦肯锡公司前高管南希·基耶弗(Nancy Killefer)和<a href=\"https://laohu8.com/S/EL\">雅诗兰黛</a>首席财务官特蕾西·特拉维斯(Tracey Travis)也相继加入董事会。目前董事会有11名成员，股东投票定于5月份举行。</p>\n<p>至此，Facebook在2019年初的九名公司董事中只有4人留任。他们分别是扎克伯格、桑德伯格、安德森和风险投资家彼得·蒂尔(Peter Thiel)。</p>\n<p>董事会的调整并没有影响到扎克伯格的其他举措。Facebook宣布向小企业提供1亿美元的援助，Facebook广告销售额中很大一部分都来自小企业。另外公司还将向新闻行业提供1亿美元的援助。</p>\n<p><img src=\"https://static.tigerbbs.com/c630f91cc1c58ce03a38cf6838bd97f0\"><i>今年2月份，扎克伯格在德国慕尼黑举行的一次会议上</i></p>\n<p>4月下旬，Facebook进行了规模最大的海外投资，斥资近60亿美元收购印度一家电信运营商的股份。扎克伯格长期以来一直试图在印度扩张业务。随后，扎克伯格又宣布推出一项名为Facebook Rooms的视频聊天服务，与<a href=\"https://laohu8.com/S/ZM\">Zoom</a>进行竞争。“我们将在相当长的一段时间内应对这种情况，”扎克伯格这样说。</p>","source":"GGFM","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook董事会大洗牌，看小扎如何控制社交帝国</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook董事会大洗牌，看小扎如何控制社交帝国\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-05-09 17:08 北京时间&nbsp;&nbsp;&nbsp;<a href=https://new.qq.com/omn/20200508/20200508A0J5UV00.html><strong>硅谷封面</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>编者按：Facebook首席执行官马克 扎克伯格(Mark Zuckerberg)相对低调，长期以来总是依靠首席运营官桑德伯格来处理政策和运营问题，依靠首席产品官考克斯来监管平台的许多重大变化。但随着Facebook在虚假信息传播、用户数据监管失之于宽、公司竞争方式等诸多方面频频遭受非议，这位35岁的社交媒体大亨开始走上前台，通过董事会大洗牌获得对公司管理的更多控制权，并试图通过公司在应对疫情中的...</p>\n\n<a href=\"https://new.qq.com/omn/20200508/20200508A0J5UV00.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/9e651bf4e105f2ad0a73eeb437e1d161","relate_stocks":{},"source_url":"https://new.qq.com/omn/20200508/20200508A0J5UV00.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166051331","content_text":"编者按：Facebook首席执行官马克 扎克伯格(Mark Zuckerberg)相对低调，长期以来总是依靠首席运营官桑德伯格来处理政策和运营问题，依靠首席产品官考克斯来监管平台的许多重大变化。但随着Facebook在虚假信息传播、用户数据监管失之于宽、公司竞争方式等诸多方面频频遭受非议，这位35岁的社交媒体大亨开始走上前台，通过董事会大洗牌获得对公司管理的更多控制权，并试图通过公司在应对疫情中的一系列高调举措扭转公众印象。\n\n以下为文章正文：\n去年12月，社交媒体公司Facebook的高管们齐聚在马克 扎克伯格(Mark Zuckerberg)位于夏威夷考艾岛(Kauai)的海滨别墅。在这座占地700多英亩的私人宅邸内，扎克伯格主持召开了一次非同寻常的董事会，讨论在公司经历多年动荡之后该如何调整运营方向。\n据知情人士透露，会上确定的一些变化让很多人始料未及。\n几个月后Facebook宣布两位董事离职，并将扎克伯格的一位老朋友吸收进公司董事会。过去两年中，扎克伯格为巩固自身决策权而采取了一系列行动，这些举措也标志着其行动达到了高峰。扎克伯格还指导Facebook在应对新型冠状病毒疫情方面开展了一系列高调活动，将自己置于媒体的聚光灯下。\n其带来的结果是，这位Facebook首席执行官和董事长比过去几年更积极、更明显地担起自己在管理公司方面的职责。\n在此之前的三年多时间中，Facebook一直因在虚假信息传播、用户数据监管失之于宽、公司竞争方式等诸多方面存在的问题而引发各种争议。目前还不能确定，扎克伯格对Facebook的重新定位以及自己在公司高层的角色转变，是否能给Facebook的声誉带来持久转变。\n长期任职的董事以及过去两年中几位长期副手的离职，意味着扎克伯格正在没有关键顾问、或许没人帮忙发现潜在陷阱的情况度过这一时期。\n扎克伯格拒绝置评。Facebook的一位发言人说：“Facebook的根本使命是建立联系，而联系从来没有像现在这样如此重要。”\n从某种程度上而言，扎克伯格是按照他在2017年2月发布的近6000字宣言来定位Facebook。在此之中他设想Facebook是“社会基础设施”，可以帮助解决疾病等全球问题。然而，这个雄心勃勃的愿景却被外部势力操纵平台、剑桥分析公司不当访问用户数据等嘈杂声音掩盖了。\n不少联邦以及州层面的政府机构一直在调查Facebook。美国联邦贸易委员会（FCC）于2018年开始调查公司的用户数据问题，去年7月与Facebook达成了创纪录的50亿美元和解协议。\nFacebook应用\n长期以来，扎克伯格一直依靠首席运营官、事实上的副手雪莉·桑德伯格(Sheryl Sandberg)来处理政策和运营问题，依靠首席产品官、老朋友克里斯·考克斯(Chris Cox)来监管平台的许多重大调整和变化。\n扎克伯格在2018年担负起了公司战时领导人的角色，不仅常常需要迅速采取行动，有时还需要单方作出决策。他宣布了一系列将Facebook引向新方向的产品，从2019年3月发布的声明开始，公司着重强调私有加密信息，而不是出名的公开信息。\n扎克伯格说，新的关注重点将使Facebook更像家中客厅而非城镇广场。这也让扎克伯格在Instagram和WhatsApp上获得了新的管理权，此前他曾承诺要独立运营这两家公司。\n消息公布后不久，曾被视为扎克伯格潜在继任者的考克斯出人意料辞职。此时距离考克斯入职Facebook已经有13年的时间。\n据知情人士透露，考克斯担心，向加密技术的转变会妨碍对恐怖主义和贩卖儿童等犯罪活动的调查。\n去年4月，Facebook披露两名长期独立董事将离开董事会。他们分别是Netflix 首席执行官里德·哈斯廷斯(Reed Hastings)和前投资银行家、克林顿政府官员厄斯金·鲍尔斯(Erskine Bowles)。\n据一位直接了解鲍尔斯的人士透露，鲍尔斯离职后曾私下批评Facebook的领导层没有听取他在政府政策方面的建议，而这正是鲍尔斯的专长所在。鲍尔斯拒绝置评。哈斯廷斯的发言人也没有回复置评请求。\n去年10月Facebook表示，自2015年6月起担任首席独立董事的苏珊 德斯蒙德-赫尔曼(Susan Desmond-Hellmann)将离开董事会。Facebook援引德斯蒙德-赫尔曼的话说，其离职是出于身体健康和家庭原因。一位知情人士则说，德斯蒙德-赫尔曼私下向一些人表示，自己离开Facebook的部分原因是她认为董事会运作不正常，而且Facebook管理层不会考虑董事会的意见。\n今年4月份，德斯蒙德-赫尔曼加入了制药巨头辉瑞公司的董事会。记者上周联系到德斯蒙德-赫尔曼请她置评有关离职Facebook的问题。她说Facebook的新闻稿是准确的，并对相关人士的描述提出了质疑。\n掌权\n据知情人士透露，扎克伯格去年12月在位于夏威夷的私人宅邸主持召开董事会会议，希望借助当地优美环境缓和一下紧张局势。\n会上董事和高管们审视了公司所面临的越来越多监管问题，包括Facebook将如何应对涉及要求复杂的美国联邦贸易委员会和解协议。这些人士说，他们讨论了公司战略、文化和治理方面的诸多问题。其中一位知情人士说，一些人在结束会议时感觉情况可能会好转。\n然而在下个月的财报电话会议上，扎克伯格似乎已经开始从道歉作出改变。他说，Facebook过去没有明确表达过自己的观点，“因为我们担心冒犯别人”。“我下一个十年的目标不是让人喜欢，而是让人理解。”\n扎克伯格需要赢得更多的董事会支持。知情人士称，他一直与任职时间最长的董事之一、风险投资大师马克 安德森(Marc Andreessen)意见不合。其中一名知情人士说，在Facebook努力遵守美国联邦贸易委员会和解协议的过程中，两人“各执一词、互不相让”。\n知情人士说，安德森向一些人表露出自己对Facebook是否有能力并愿意遵守这些条款感到失望的态度，并考虑离开董事会。安德森-霍洛维茨基金的发言人拒绝置评。\nFacebook发言人说，安德森从未怀疑过公司遵守和解协议的能力或承诺。\n去年春天，PayPal高管佩吉 阿尔福德(Peggy Alford)加入了Facebook董事会。阿尔福德曾在扎克伯格手下担任基金会“陈-扎克伯格行动”(Chan Zuckerberg Initiative)的首席财务官。今年2月份，扎克伯格在董事会获得了更多支持，其老朋友、云软件公司Dropbox首席执行官德鲁 休斯顿(Drew Houston)也加入进来。\n休斯顿的发言人拒绝置评。阿尔福德没有回复记者的置评请求。\n当新型冠状病毒疫情在美国蔓延开来时，扎克伯格迅速动员起整个Facebook。3月2日，他召集公司业务和产品部门的高级代表开会讨论应对措施。\n知情人士说，扎克伯格和其他高层领导人认为Facebook有机会发挥重要作用。参与讨论的一名人士表示，他们要求高管们想出一个“有助于改变公众对Facebook看法”的好主意。\n其中一个想法是开展一场声势浩大的广告宣传活动，向Facebook用户打出这样的口号：“如果我们能找到彼此，我们就永远不会迷路。”\n公司发言人则反驳了扎克伯格曾鼓励参会代表们将Facebook反应视为一次公关良机的说辞。这位发言人表示：“任何声誉提升都将是这项工作的副产品，而不是驱动因素。”\n3月初的一个周末，20名高级管理人员又在扎克伯格位于加州帕洛阿尔托(Palo Alto)的住所内参与了一个名为新型冠状病毒信息中心(coronavirus information hub)的项目，其中包括诸如提醒保持社交距离等功能。几天之内这个项目就上线了。\n调整\n3月中旬，Facebook宣布美国运通(American Express)前首席执行官肯尼斯 切诺特(Kenneth Chenault)将离开董事会。\n他和扎克伯格一度关系密切。据一名熟悉二人关系的人士透露，在2018年2月加入董事会之前，扎克伯格有段时间每周都会给切诺特打电话征求意见，把他当作懂得如何管理大型机构的“善良叔叔”。\nFacebook董事会成员的调整变化\n但现在切诺特已经幡然醒悟。据知情人士透露，在加入Facebook后不久，切诺特就试图创建一个专门研究Facebook问题的外部咨询小组，并绕开扎克伯格直接向董事会提交报告。结果董事会里的其他人提出反对意见，这个主意最终落空了。\n美国运通前首席执行官肯尼斯 切诺特(Kenneth Chenault)\n在Facebook宣布离职的声明中，切诺特说自己之所以离职，是因为能加入伯克希尔哈撒韦公司董事会，这一机会千载难逢。\n大约两周后，Facebook表示齐恩茨也将离开董事会，腾出更多时间处理自家业务。知情人士说，数月来切诺特和齐恩茨都对整个管理层以及公司处理错误信息的方式感到不满。\n今年3月份，Facebook任命前美国副财长、商人罗伯特·M·金米特(Robert M. Kimmitt)为首席独立董事。麦肯锡公司前高管南希·基耶弗(Nancy Killefer)和雅诗兰黛首席财务官特蕾西·特拉维斯(Tracey Travis)也相继加入董事会。目前董事会有11名成员，股东投票定于5月份举行。\n至此，Facebook在2019年初的九名公司董事中只有4人留任。他们分别是扎克伯格、桑德伯格、安德森和风险投资家彼得·蒂尔(Peter Thiel)。\n董事会的调整并没有影响到扎克伯格的其他举措。Facebook宣布向小企业提供1亿美元的援助，Facebook广告销售额中很大一部分都来自小企业。另外公司还将向新闻行业提供1亿美元的援助。\n今年2月份，扎克伯格在德国慕尼黑举行的一次会议上\n4月下旬，Facebook进行了规模最大的海外投资，斥资近60亿美元收购印度一家电信运营商的股份。扎克伯格长期以来一直试图在印度扩张业务。随后，扎克伯格又宣布推出一项名为Facebook Rooms的视频聊天服务，与Zoom进行竞争。“我们将在相当长的一段时间内应对这种情况，”扎克伯格这样说。","news_type":1},"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":927902949,"gmtCreate":1588688478181,"gmtModify":1704178070049,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"今天油股都在涨，不过得小心哦，开始涨跌不一了","listText":"今天油股都在涨，不过得小心哦，开始涨跌不一了","text":"今天油股都在涨，不过得小心哦，开始涨跌不一了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/927902949","isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":924340697,"gmtCreate":1588237225619,"gmtModify":1704367039137,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"看来今年大选各方布局都是拼命把各自的饼画得又大又美","listText":"看来今年大选各方布局都是拼命把各自的饼画得又大又美","text":"看来今年大选各方布局都是拼命把各自的饼画得又大又美","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924340697","isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":944493484,"gmtCreate":1597071442748,"gmtModify":1704214309276,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","listText":"<a href=\"https://laohu8.com/S/SRNE\">$Sorrento Therapeutics Inc.(SRNE)$</a>我也成绩不错","text":"$Sorrento Therapeutics Inc.(SRNE)$我也成绩不错","images":[{"img":"https://static.tigerbbs.com/d1c25d50891643ebcf0c1815243ee16b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/944493484","isVote":1,"tweetType":1,"viewCount":741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":924002462,"gmtCreate":1588162165556,"gmtModify":1704366655891,"author":{"id":"3542328439002885","authorId":"3542328439002885","name":"helen88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"赌场是在困景中恢复最快的行业，一半本金在股市，一半就去赌场买一手大小[龇牙]&nbsp;[龇牙]&nbsp;[龇牙]&nbsp;","listText":"赌场是在困景中恢复最快的行业，一半本金在股市，一半就去赌场买一手大小[龇牙]&nbsp;[龇牙]&nbsp;[龇牙]&nbsp;","text":"赌场是在困景中恢复最快的行业，一半本金在股市，一半就去赌场买一手大小[龇牙] [龇牙] [龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924002462","isVote":1,"tweetType":1,"viewCount":157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}